{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:38:34Z","timestamp":1784864314135,"version":"3.55.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["506071"],"award-info":[{"award-number":["506071"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Frontiers in Neuroendocrinology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.yfrne.2024.101156","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T05:33:19Z","timestamp":1727674399000},"page":"101156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effect of 5-alpha reductase inhibitors in animal models of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"75","author":[{"given":"M\u00e9lanie","family":"Bourque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Morissette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Isenbrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Giatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Cosimo","family":"Melcangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolo","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Frau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bortolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Soulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yfrne.2024.101156_b0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and Treatment of Parkinson Disease: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.yfrne.2024.101156_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135164","article-title":"Remodeling microglia to a protective phenotype in Parkinson's disease?","volume":"735","author":"Awogbindin","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.yfrne.2024.101156_b0015","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00415-005-0835-7","article-title":"Gender and the Parkinson's disease phenotype","volume":"252","author":"Baba","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.yfrne.2024.101156_b0020","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/mds.23878","article-title":"Projected numbers of people with movement disorders in the years 2030 and 2050","volume":"26","author":"Bach","year":"2011","journal-title":"Movement Disorders : Off. J. Movement Disorder Soc."},{"key":"10.1016\/j.yfrne.2024.101156_b0025","article-title":"Brain region- and sex-specific transcriptional profiles of microglia","volume":"13","author":"Barko","year":"2022","journal-title":"Front. Psych."},{"key":"10.1016\/j.yfrne.2024.101156_b0030","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1111\/ene.15607","article-title":"Intestinal histomorphological and molecular alterations in patients with Parkinson's disease","volume":"30","author":"Bellini","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.yfrne.2024.101156_b0035","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm875","article-title":"Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function","volume":"9","author":"B\u00e9zard","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.yfrne.2024.101156_b0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.parkreldis.2015.11.007","article-title":"Risk and course of motor complications in a population-based incident Parkinson's disease cohort","volume":"22","author":"Bjornestad","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.yfrne.2024.101156_b0045","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1038\/npp.2008.39","article-title":"Antipsychotic-like properties of 5-alpha-reductase inhibitors","volume":"33","author":"Bortolato","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.yfrne.2024.101156_b0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/WNF.0b013e3181dca96f","article-title":"Treatment of benign essential blepharospasm with finasteride: a case report","volume":"33","author":"Bortolato","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.yfrne.2024.101156_b0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/JCP.0b013e3182549c2a","article-title":"Finasteride attenuates pathological gambling in patients with Parkinson disease","volume":"32","author":"Bortolato","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.yfrne.2024.101156_b0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.yfrne.2012.02.003","article-title":"Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease","volume":"33","author":"Bourque","year":"2012","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.yfrne.2024.101156_b0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neuropharm.2015.04.006","article-title":"Neuroprotection in Parkinsonian-treated mice via estrogen receptor \u03b1 activation requires G protein-coupled estrogen receptor 1","volume":"95","author":"Bourque","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yfrne.2024.101156_b0070","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000438789","article-title":"Neuroprotective Effect of Progesterone in MPTP-Treated Male Mice","volume":"103","author":"Bourque","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.yfrne.2024.101156_b0075","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.3390\/cells11223530","article-title":"AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys","volume":"11","author":"Bourque","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.yfrne.2024.101156_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2023.110668","article-title":"Impact of sex on neuroimmune contributions to Parkinson's disease","volume":"199","author":"Bourque","year":"2023","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.yfrne.2024.101156_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105479","article-title":"Neuroactive steroids and Parkinson's disease: Review of human and animal studies","volume":"156","author":"Bourque","year":"2024","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.yfrne.2024.101156_b0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.yfrne.2024.101156_b0095","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","article-title":"Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen","volume":"110","author":"Braak","year":"2003","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.yfrne.2024.101156_b0100","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.yfrne.2024.101156_b0105","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.steroids.2012.03.011","article-title":"Neurosteroid binding to the amino terminal and glutamate binding domains of ionotropic glutamate receptors","volume":"77","author":"Cameron","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.yfrne.2024.101156_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105697","article-title":"Striatal glutamatergic hyperactivity in Parkinson's disease","volume":"168","author":"Campanelli","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.yfrne.2024.101156_b0115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cell.2010.06.001","article-title":"SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder","volume":"142","author":"Cantagrel","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.yfrne.2024.101156_b0120","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00702-018-1865-5","article-title":"The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective","volume":"125","author":"Carta","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.yfrne.2024.101156_b0125","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.yfrne.2024.101156_b0130","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1365-2826.2010.02064.x","article-title":"Effect of short-and long-term gonadectomy on neuroactive steroid levels in the central and peripheral nervous system of male and female rats","volume":"22","author":"Caruso","year":"2010","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.yfrne.2024.101156_b0135","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.psyneuen.2013.04.016","article-title":"Comparison of plasma and cerebrospinal fluid levels of neuroactive steroids with their brain, spinal cord and peripheral nerve levels in male and female rats","volume":"38","author":"Caruso","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.yfrne.2024.101156_b0140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.psyneuen.2012.06.008","article-title":"Regional distribution of 5\u03b1-reductase type 2 in the adult rat brain: an immunohistochemical analysis","volume":"38","author":"Castelli","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.yfrne.2024.101156_b0145","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson's Disease in Women and Men: What's the Difference?","volume":"9","author":"Cerri","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.yfrne.2024.101156_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/biom12020243","article-title":"Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease","volume":"12","author":"Chagraoui","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.yfrne.2024.101156_b0155","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/jc.2003-030330","article-title":"Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5\u03b1-Reductase Inhibitor","volume":"89","author":"Clark","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.yfrne.2024.101156_b0160","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Collaborators","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.yfrne.2024.101156_b0165","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/787451","article-title":"The \u201cgender factor\u201d in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study","volume":"2015","author":"Colombo","year":"2015","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.yfrne.2024.101156_b0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/cr.2011.9","article-title":"Taming of macrophage and microglial cell activation by microRNA-124","volume":"21","author":"Conrad","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.yfrne.2024.101156_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2023.114370","article-title":"Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease","volume":"363","author":"Corsi","year":"2023","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.yfrne.2024.101156_b0180","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbi.2015.01.009","article-title":"Partial depletion of the proinflammatory monocyte population is neuroprotective in the myenteric plexus but not in the basal ganglia in a MPTP mouse model of Parkinson's disease","volume":"46","author":"C\u00f4t\u00e9","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.yfrne.2024.101156_b0185","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1124\/mol.105.018671","article-title":"Implication of the phosphatidylinositol-3 kinase\/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice","volume":"69","author":"D'Astous","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.yfrne.2024.101156_b0190","doi-asserted-by":"crossref","unstructured":"Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., Bruley des Varannes, S., Naveilhan, P., Nguyen, J.M., Neunlist, M., and Derkinderen, P., 2013. Colonic inflammation in Parkinson's disease. Neurobiology of disease 50, 42-8. https:\/\/doi.org\/10.1016\/j.nbd.2012.09.007.","DOI":"10.1016\/j.nbd.2012.09.007"},{"key":"10.1016\/j.yfrne.2024.101156_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134427","article-title":"Levodopa-Induced Dyskinesias in Parkinson's Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions","volume":"12","author":"di Biase","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.yfrne.2024.101156_b0200","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s10072-003-0115-1","article-title":"Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease","volume":"24","author":"di Michele","year":"2003","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.yfrne.2024.101156_b0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0006-8993(95)01566-3","article-title":"Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57\/B1 mice","volume":"715","author":"Dluzen","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.yfrne.2024.101156_b0210","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1365-2826.2002.00833.x","article-title":"Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice","volume":"14","author":"Ekue","year":"2002","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.yfrne.2024.101156_b0215","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.nbd.2018.09.018","article-title":"5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1\u2013D3 receptor interaction","volume":"121","author":"Fanni","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.yfrne.2024.101156_b0220","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.brainresbull.2022.01.020","article-title":"The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting","volume":"181","author":"Floris","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.yfrne.2024.101156_b0225","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.psyneuen.2012.07.014","article-title":"Inhibition of 5\u03b1-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL\/6 mice","volume":"38","author":"Frau","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.yfrne.2024.101156_b0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.psyneuen.2015.09.014","article-title":"The neurosteroidogenic enzyme 5\u03b1-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating","volume":"63","author":"Frau","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.yfrne.2024.101156_b0235","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/npp.2017.13","article-title":"The Neurosteroidogenic Enzyme 5\u03b1-Reductase Mediates Psychotic-Like Complications of Sleep Deprivation","volume":"42","author":"Frau","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.yfrne.2024.101156_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2017.01.012","article-title":"The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease","volume":"291","author":"Frau","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.yfrne.2024.101156_b0245","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3389\/fneur.2017.00397","article-title":"Increase of Reproductive Life Span Delays Age of Onset of Parkinson's Disease","volume":"8","author":"Frentzel","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.yfrne.2024.101156_b0250","doi-asserted-by":"crossref","first-page":"e2248135","DOI":"10.1001\/jamanetworkopen.2022.48135","article-title":"Association of 5\u03b1-Reductase Inhibitors With Dementia, Depression, and Suicide","volume":"5","author":"Garcia-Argibay","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.yfrne.2024.101156_b0255","doi-asserted-by":"crossref","first-page":"e12736","DOI":"10.1111\/jne.12736","article-title":"Sex differences in the brain expression of steroidogenic molecules under basal conditions and after gonadectomy","volume":"31","author":"Giatti","year":"2019","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.yfrne.2024.101156_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2018.06.007","article-title":"Neuroactive steroids, neurosteroidogenesis and sex","volume":"176","author":"Giatti","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.yfrne.2024.101156_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2020.100836","article-title":"Physiopathological role of the enzymatic complex 5\u03b1-reductase and 3\u03b1\/\u03b2-hydroxysteroid oxidoreductase in the generation of progesterone and testosterone neuroactive metabolites","volume":"57","author":"Giatti","year":"2020","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.yfrne.2024.101156_b0270","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.pbb.2004.04.022","article-title":"Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease","volume":"78","author":"Gillies","year":"2004","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.yfrne.2024.101156_b0275","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0304-3940(92)90152-W","article-title":"Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys","volume":"135","author":"Gomez-Mancilla","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.yfrne.2024.101156_b0280","doi-asserted-by":"crossref","unstructured":"Group, G.B.D.N.D.C., 2017. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16, 877-897. https:\/\/doi.org\/10.1016\/S1474-4422(17)30299-5.","DOI":"10.1016\/S1474-4422(17)30299-5"},{"key":"10.1016\/j.yfrne.2024.101156_b0285","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1016\/j.celrep.2018.08.001","article-title":"Transcriptional and Translational Differences of Microglia from Male and Female Brains","volume":"24","author":"Guneykaya","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.yfrne.2024.101156_b0290","doi-asserted-by":"crossref","unstructured":"Gupta, A.K., Talukder, M., and Williams, G., 2024. Emerging and traditional 5-\u03b1 reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia. Expert Opin Emerg Drugs1-11. https:\/\/doi.org\/10.1080\/14728214.2024.2346590.","DOI":"10.1080\/14728214.2024.2346590"},{"key":"10.1016\/j.yfrne.2024.101156_b0295","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/jnnp.2006.103788","article-title":"Gender differences in Parkinson's disease","volume":"78","author":"Haaxma","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.yfrne.2024.101156_b0300","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000445751","article-title":"The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis","volume":"46","author":"Hirsch","year":"2016","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.yfrne.2024.101156_b0305","first-page":"56","article-title":"Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review","volume":"9","author":"Hirshburg","year":"2016","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"10.1016\/j.yfrne.2024.101156_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108784","article-title":"Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice","volume":"201","author":"Isenbrandt","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yfrne.2024.101156_b0315","article-title":"Three-Dimensional Analysis of Sex- and Gonadal Status- Dependent Microglial Activation in a Mouse Model of Parkinson's Disease","volume":"16","author":"Isenbrandt","year":"2023","journal-title":"Pharmaceuticals (basel, Switzerland)"},{"key":"10.1016\/j.yfrne.2024.101156_b0320","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson's disease: etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.yfrne.2024.101156_b0325","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.yfrne.2017.09.002","article-title":"Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics","volume":"50","author":"Jurado-Coronel","year":"2018","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.yfrne.2024.101156_b0330","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1471-4159.2010.06776.x","article-title":"Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"114","author":"Kobylecki","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.yfrne.2024.101156_b0335","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233736","article-title":"Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies","volume":"11","author":"Kwon","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.yfrne.2024.101156_b0340","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neuropharm.2015.05.015","article-title":"The 5\u03b1-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease","volume":"97","author":"Litim","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yfrne.2024.101156_b0345","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jsbmb.2017.09.021","article-title":"Effect of the 5\u03b1-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice","volume":"174","author":"Litim","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.yfrne.2024.101156_b0350","first-page":"10584","article-title":"The clinical applications of five-alpha reductase inhibitors","volume":"28","author":"Loughlin","year":"2021","journal-title":"Can. J. Urol."},{"key":"10.1016\/j.yfrne.2024.101156_b0355","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1750-3639.2010.00396.x","article-title":"Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease","volume":"20","author":"Luchetti","year":"2010","journal-title":"Brain Pathol."},{"key":"10.1016\/j.yfrne.2024.101156_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106169","article-title":"Disease stage-dependent changes in brain levels and neuroprotective effects of neuroactive steroids in Parkinson's disease","volume":"183","author":"Luchetti","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.yfrne.2024.101156_b0365","doi-asserted-by":"crossref","first-page":"26016","DOI":"10.1074\/jbc.M710349200","article-title":"Identification of dopamine D1\u2013D3 receptor heteromers. Indications for a role of synergistic D1\u2013D3 receptor interactions in the striatum","volume":"283","author":"Marcellino","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yfrne.2024.101156_b0370","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-024-02774-2","article-title":"Current trends in basic research on Parkinson's disease: from mitochondria, lysosome to \u03b1-synuclein","author":"Matsui","year":"2024","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.yfrne.2024.101156_b0375","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00018-007-7403-5","article-title":"Neuroactive steroids: state of the art and new perspectives","volume":"65","author":"Melcangi","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.yfrne.2024.101156_b0380","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12031-011-9570-y","article-title":"Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson's disease","volume":"46","author":"Melcangi","year":"2012","journal-title":"J. Molecular Neuroscience : MN"},{"key":"10.1016\/j.yfrne.2024.101156_b0385","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.nbd.2018.09.021","article-title":"NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology","volume":"121","author":"Mellone","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.yfrne.2024.101156_b0390","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.1998.tb08230.x","article-title":"The impact of gender and estrogen on striatal dopaminergic neurotoxicity","volume":"844","author":"Miller","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.yfrne.2024.101156_b0395","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.neuropharm.2015.08.002","article-title":"Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications","volume":"99","author":"Morin","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yfrne.2024.101156_b0400","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/mds.23810","article-title":"A preliminary study of finasteride in Tourette syndrome","volume":"26","author":"Muroni","year":"2011","journal-title":"Movement Disorders : Official Journal of the Movement Disorder Society"},{"key":"10.1016\/j.yfrne.2024.101156_b0405","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0306-4522(02)00578-X","article-title":"Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females","volume":"116","author":"Murray","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.yfrne.2024.101156_b0410","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ane.12334","article-title":"Prolactin and sex hormones levels in males with Parkinson's disease","volume":"131","author":"Nitkowska","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.yfrne.2024.101156_b0415","first-page":"165","article-title":"Testosterone deficiency in a Parkinson's disease clinic: results of a survey","volume":"75","author":"Okun","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.yfrne.2024.101156_b0420","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12031-008-9137-8","article-title":"Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61\u20138048 in MPTP monkeys with levodopa-induced dyskinesias","volume":"38","author":"Ouattara","year":"2009","journal-title":"Journal of Molecular Neuroscience : MN"},{"key":"10.1016\/j.yfrne.2024.101156_b0425","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neuroscience.2010.03.022","article-title":"Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias","volume":"167","author":"Ouattara","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.yfrne.2024.101156_b0430","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2009.07.014","article-title":"Metabotropic glutamate receptor type 5 in levodopa-induced motor complications","volume":"32","author":"Ouattara","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.yfrne.2024.101156_b0435","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neurobiolaging.2016.08.004","article-title":"Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse model of Parkinson's disease","volume":"48","author":"Poirier","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.yfrne.2024.101156_b0440","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.898067","article-title":"Peripheral Neuroprotective and Immunomodulatory Effects of 5\u03b1-Reductase Inhibitors in Parkinson's Disease Models","volume":"13","author":"Poirier","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yfrne.2024.101156_b0445","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-381328-2.00002-X","article-title":"l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment","volume":"98","author":"Prashanth","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.yfrne.2024.101156_b0450","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/mds.870130520","article-title":"New use for an old drug: amantadine benefits levodopa-induced dyskinesia","volume":"13","author":"Rajput","year":"1998","journal-title":"Movement Disorders : Official Journal of the Movement Disorder Society"},{"key":"10.1016\/j.yfrne.2024.101156_b0455","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1460-9568.2011.07675.x","article-title":"Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias","volume":"33","author":"Riahi","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.yfrne.2024.101156_b0460","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/mds.27063","article-title":"Projection of the prevalence of Parkinson's disease in the coming decades: Revisited","volume":"33","author":"Rossi","year":"2018","journal-title":"Movement Disorders : Official Journal of the Movement Disorder Society"},{"key":"10.1016\/j.yfrne.2024.101156_b0465","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/mds.25988","article-title":"In vivo gastric detection of \u03b1-synuclein inclusions in Parkinson's disease","volume":"30","author":"S\u00e1nchez-Ferro","year":"2015","journal-title":"Movement Disorders : Official Journal of the Movement Disorder Society"},{"key":"10.1016\/j.yfrne.2024.101156_b0470","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.yhbeh.2012.05.013","article-title":"Risk factors for Parkinson's disease may differ in men and women: an exploratory study","volume":"63","author":"Savica","year":"2013","journal-title":"Horm. Behav."},{"key":"10.1016\/j.yfrne.2024.101156_b0475","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pharmthera.2018.06.011","article-title":"Neurosteroids: non-genomic pathways in neuroplasticity and involvement in neurological diseases","volume":"191","author":"Schverer","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.yfrne.2024.101156_b0480","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.expneurol.2014.04.011","article-title":"Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease","volume":"257","author":"Shin","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.yfrne.2024.101156_b0485","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00702-018-1847-7","article-title":"Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression","volume":"125","author":"Spigolon","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.yfrne.2024.101156_b0490","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s12035-023-03679-z","article-title":"Neuroimmune Connectomes in the Gut and Their Implications in Parkinson's Disease","volume":"61","author":"Thomasi","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.yfrne.2024.101156_b0495","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/mds.10305","article-title":"Systematic review of incidence studies of Parkinson's disease","volume":"18","author":"Twelves","year":"2003","journal-title":"Movement Disorders : Official Journal of the Movement Disorder Society"},{"key":"10.1016\/j.yfrne.2024.101156_b0500","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1349-7006.2007.00656.x","article-title":"Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer","volume":"99","author":"Uemura","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.yfrne.2024.101156_b0505","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nbd.2008.11.010","article-title":"Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease","volume":"35","author":"Visanji","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.yfrne.2024.101156_b0510","doi-asserted-by":"crossref","DOI":"10.3390\/cells12192336","article-title":"Astrocytes in Parkinson's Disease: From Role to Possible Intervention","volume":"12","author":"Wang","year":"2023","journal-title":"Cells"}],"container-title":["Frontiers in Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091302224000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091302224000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T23:03:46Z","timestamp":1731711826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091302224000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":102,"alternative-id":["S0091302224000360"],"URL":"https:\/\/doi.org\/10.1016\/j.yfrne.2024.101156","relation":{},"ISSN":["0091-3022"],"issn-type":[{"value":"0091-3022","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of 5-alpha reductase inhibitors in animal models of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Frontiers in Neuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yfrne.2024.101156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101156"}}